Drug intelligence / Profile preview

111In-Accum-trastuzumab

Development stage: Preclinical
Lead developer: Defence Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Parenteral

Overview

**111In-Accum-trastuzumab** is a preclinical, Accum-enhanced HER2-targeted radioimmunoconjugate program being developed for HER2-positive solid tumors, including tumors resistant to established HER2-directed therapies. It uses trastuzumab for HER2 recognition and indium-111 as an Auger-electron-emitting radionuclide. Defence Therapeutics' Accum intracellular-delivery technology is intended to promote endosomal escape and nuclear localization after HER2-mediated cellular uptake, positioning indium-111 near DNA to produce localized radiation-induced DNA damage and cancer-cell killing. Public sponsor materials describe the related constructs as variations of **111In-AccuTOX-trastuzumab**, with candidate selection and preclinical characterization ongoing. ([defencetherapeutics.com](https://defencetherapeutics.com/defence-therapeutics-granted-cnri-h-from-the-canadian-nuclear-laboratories-to-accelerate-the-development-of-its-radio-immuno-conjugates-program/))

Other names: 111In-Accum-trastuzumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 111In-Accum-trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 111In-Accum-trastuzumab.

Explore the full profile